Flexion proposes follow-on after FDA hold lifted

Flexion Therapeutics Inc. (NASDAQ:FLXN) proposed to raise up to $69 million in a follow-on underwritten by BMO and RBC.

The news came after Flexion announced postmarket Monday that FDA lifted a clinical hold on FX006 to treat osteoarthritis (OA) knee pain. The company intends to immediately resume a pivotal Phase IIb trial of the sustained-release intra-articular formulation of triamcinolone acetonide (see BioCentury Extra, Dec. 1). ...